TWST Q2 2026 Earnings Call Summary

Summary of Twist Biosciences Q2 2026 Earnings Call

1. Key Financial Results and Metrics

Total Revenue: $110.7 million, up 19.3% year-over-year, marking the 13th consecutive quarter of sequential growth.
Gross Margin: Expanded to 51.6%, an improvement of approximately 200 basis points year-over-year.
Adjusted EBITDA: Loss of $13.3 million, an improvement of $1.5 million compared to the same quarter last year.
Cash Position: Ended Q2 with $171.7 million in cash and equivalents, down from $197.9 million at the end of Q1.
Revenue Breakdown:
- DNA Synthesis and Protein Solutions: $53.3 million (28% growth).
- NGS Applications: $57.4 million (12% growth year-over-year, 9% sequentially).

2. Strategic Updates and Business Highlights

Continued strong performance in AI-enabled drug discovery and NGS applications, with significant partnerships, including being named a wet lab partner for Amazon BioDiscovery.
Expansion of product offerings, including a licensed bispecific platform, enhancing capabilities in a rapidly growing market.
Investment in digital infrastructure and commercial organization to support growth, particularly in therapeutics which saw a 55% revenue increase.
Ongoing improvements in the acceptance rate of DNA sequences, aiming for 99.5% acceptance of clonal genes.

3. Forward Guidance and Outlook

Fiscal 2026 Revenue Guidance: Expected to be between $442 million and $447 million, reflecting growth of approximately 17% to 19%.
Q3 Revenue Guidance: Anticipated revenue of $114 million to $115 million, representing approximately 19% year-over-year growth.
Confident in reaching adjusted EBITDA breakeven by Q4 of fiscal 2026.

4. Bad News, Challenges, or Points of Concern

Academic and Government Market: Facing funding pressures, leading to cautious spending and slower growth compared to other segments.
Gross Margin: Although improved year-over-year, there was a nominal sequential decline, raising concerns about cost management amidst ongoing investments.
Litigation Settlement: A securities class action settlement of approximately $17.1 million was reached, which may impact cash reserves.

5. Notable Q&A Insights

AI-Driven Workflows: AI has significantly contributed to growth, with many customers now leveraging AI for drug discovery, leading to increased demand for diverse DNA sequences.
Market Dynamics: The company is capturing market share in the academic sector despite funding challenges, indicating strong product resonance.
Future Growth: Management expressed confidence in sustaining growth across all segments, particularly in NGS and therapeutics, with a focus on expanding customer engagement.
Operational Efficiency: Plans to automate workflows further to enhance capacity and efficiency, which could lead to improved margins in the future.

Overall, Twist Biosciences demonstrated robust financial performance and strategic execution in Q2 2026, while also acknowledging challenges in certain market segments and the need for continued investment in operational improvements.

TWST — Twist Bioscience Corporation